Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:EIDX

Eidos Therapeutics (EIDX) Stock Price, News & Analysis

Eidos Therapeutics logo

About Eidos Therapeutics Stock (NASDAQ:EIDX)

Key Stats

Today's Range
$122.21
$122.21
50-Day Range
$120.98
$128.51
52-Week Range
$28.39
$132.54
Volume
N/A
Average Volume
128,113 shs
Market Capitalization
$4.75 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.

Receive EIDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eidos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

EIDX Stock News Headlines

Cackling Kamala hates this company
Do you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution.
The Anglo File: Game Over for Board Lapses at Eidos
See More Headlines

EIDX Stock Analysis - Frequently Asked Questions

Eidos Therapeutics, Inc. (NASDAQ:EIDX) released its quarterly earnings results on Thursday, October, 29th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by $0.08. The company earned $0.13 million during the quarter.

Eidos Therapeutics (EIDX) raised $101 million in an initial public offering (IPO) on Wednesday, June 20th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Barclays was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eidos Therapeutics investors own include Bristol-Myers Squibb (BMY), CRISPR Therapeutics (CRSP), Exelixis (EXEL), NVIDIA (NVDA), Micron Technology (MU), Axsome Therapeutics (AXSM) and Occidental Petroleum (OXY).

Company Calendar

Last Earnings
10/29/2020
Today
12/22/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EIDX
CIK
N/A
Fax
N/A
Employees
70
Year Founded
N/A

Profitability

Net Income
$-37,830,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$26.69 million
Book Value
$4.57 per share

Miscellaneous

Free Float
N/A
Market Cap
$4.75 billion
Optionable
Not Optionable
Beta
-0.16
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:EIDX) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners